Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma

Haematologica

Volumn 96, Issue 2, 2011, Pages 238-244

  Gökbuget, Nicola ^a   Hartog, Christina Maria ^a   Bassan, Renato ^b   Derigs, Heinz Gerd ^c   Dombret, Herve ^d   Greil, Richard ^e   Hernández Rivas, Jesus Maria ^f   Huguet, Francoise ^g   Intermesoli, Tamara ^b   Jourdan, Eric ^h   Junghanss, Christian ⁱ   Leimer, Lothar ^j   Moreno, Maria Jose ^k   Reichle, Albrecht ^l   Ribera, Josep ^m   Schmid, Matthias ⁿ   Serve, Hubert ^a   Stelljes, Matthias ^o   Stuhlmann, Reingard ^p   Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b OSPEDALI RIUNITI   (Italy)

^c Eye Hospital   (Germany)

^d SAINT LOUIS HOSPITAL   (France)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g CHU PURPAN   (France)

^h DEPARTMENT OF NEUROLOGY   (France)

ⁱ UNIVERSITY OF ROSTOCK   (Germany)

^j ROBERT BOSCH HOSPITAL   (Germany)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^l UNIVERSITY OF REGENSBURG   (Germany)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁿ UNIVERSITY OF ULM   (Germany)

^o UNIVERSITY OF MÜNSTER   (Germany)

^p DEPARTMENT OF CARDIOLOGY   (Germany)

more..

Author keywords

Acute lymphoblastic leukemia; Adults; Aggressive lymphoma; Cns relapse; Liposomal cytarabine

Indexed keywords

CYTARABINE; DEXAMETHASONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARACHNOIDITIS; ARTICLE; ATAXIA; BRAIN METASTASIS; BURKITT LYMPHOMA; CANCER REGRESSION; CANCER RELAPSE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CRANIAL NEUROPATHY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GAIT DISORDER; HEADACHE; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; LYMPHOMA; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGICAL COMPLICATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SEIZURE; SENSORY NEUROPATHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; FEMALE; HUMANS; INTERNATIONAL AGENCIES; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79551679044     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.028092     Document Type: Article

References (27)

1. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Sem Hematol. 2009;46(1):64-75.
2. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257-68.
3. Gökbuget N, Aguion-Freire E, Diedrich H Digel W, Faak T, Kasper C, et al. Characteristics and outcome of CNS relapse in patients with acute lymphoblastic leukemia (ALL). Blood. 1999;94(10): 1287a.
4. Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94 (3):773-9.
5. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-14.
6. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-50.
7. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranialirradiation for prophylaxis. Cancer. 2006;106(12): 2540-6.
8. Chamberlain MC. Leukemia and the nervous system. Curr Oncol Rep. 2005;7(1):66- 73
9. Gökbuget N, Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neuro Oncol. 1998;38(2-3): 167-80.
10. Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol. 2007;81(2):201-8.
11. Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother. 2008;9(2):301-9.
12. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17(10):3110- 6.
13. Bleyer WA. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin Cancer Res. 1999;5 (11):3349-51.
14. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, Chapa-Rodriguez A, Gomez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol. 2009;144(5):794-5.
15. Sancho JM, Ribera JM, Romero MJ, Martín-Reina V, Giraldo P, Ruiz E. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica. 2006;91(3):ECR02.
16. Holowiecka-Goral A, Hołowiecki J, Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Kos K, et al. Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group. Leuk Lymphoma. 2009;50(3):478-80.
17. Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol. 2007;29(4):222-6.
18. Garcia-Marco JA, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, et al. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer. 2009;115(9):1892-8.
19. Mazhar D, Stebbing J, Lewis R et al. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood. 2006;107(8):3412-4.
20. Sancho JM, Deben G, Parker A, Piñana JL, Bolam S, Sánchez-García E, et al. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. Int J Hematol. 2007;86(1):33-6.
21. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, et al. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest. 2007;37(10):808-13.
22. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004;22(19):3916-21.
23. Sommer C, Lackner H, Benesch M, Sovinz P, Schwinger W, Moser A, et al. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Ann Hematol. 2008;87 (11):887-90.
24. Jabbour E, O'Brien S, Kantarjian H, Garcia- Manero G, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with highdose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109(8):3214-8.
25. Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, et al. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Ann Hematol. 2008;87(12):1009-12.
26. Parasole R, Menna G, Marra N, Petruzziello F, Locatelli F, Mangione A, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leuk Lymphoma. 2008;49(8):1553-9.
27. Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M, Zanet E, et al. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin's lymphoma. Cancer. 2010;116(6):1495-501.